SAB Biotherapeutics, Inc. (SABS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to SAB Bios, conference call to discuss second quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from this morning's quarterly earnings press release. Company management may provide projections during this call, and actual results could differ materially due to several factors, including those outlined in the company's latest filings with the SEC. All participants are in a listen-only mode. Following management's remarks, we will open the call for questions. This call is being webcast live and can be accessed on the Investors section of SABbio's website at ir.sab.bio where a replay will be available. I'll now turn the call over to Samuel Reich, Chief Executive Officer of of SAP Pio. Thank you, operator. Good morning, and thank you to everyone joining us for our second quarter 2025 earnings call. I'm joined today by Lucy To, our chief financial officer, who will review the second quarter financial updates. I'm also joined by Eddie Sullivan, our co-founder and president, and Alexandra Kropotova, our chief medical officer. We're pleased to have you with us today to share the progress we've made in the second quarter. We've remained focused on execution, Delivering meaningful progress in our safeguard study and advancing key clinical and operational priorities. For those who may be new to the SAV Bio story, we are a clinical stage biopharmaceutical company focused on developing disease-modifying therapies for type 1 diabetes and other autoimmune diseases. Our mission today is to redefine what it means to be diagnosed with type 1 diabetes by developing a medicine to change the course of disease. With millions of people living with type 1 diabetes worldwide, we are p...